Role of the Mycobiome in Human Acute Graft-versus-Host Disease  by van der Velden, Walter J.F.M. et al.
W.J.F.M. van der Velden et al. / Biol Blood Marrow Transplant 19 (2013) 321e332 329Role of the Mycobiome in Human Acute
Graft-versus-Host Disease
Walter J.F.M. van der Velden 1,3,*, Mihai G. Netea 2,3, Anton F.J. de Haan 4,
Gerwin A. Huls 1, J. Peter Donnelly 1,3, Nicole M.A. Blijlevens 1,3
1Department of Hematology, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands
2Department of Internal Medicine, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands
3Nijmegen Institute for Infection, Inﬂammation, and Immunity, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen,
The Netherlands
4Department of Epidemiology, Biostatistics, and Health Technology Assessment, Radboud University Nijmegen Medical Center,
6500 HB Nijmegen, The NetherlandsArticle history:
Received 9 October 2012
Accepted 8 November 2012
Key Words:
Candida colonization
GI-GVHD
Dectin-1Financial disclosure: See Acknowle
* Correspondence and reprint r
Radboud University Nijmegen Med
megen, The Netherlands .
E-mail address: W.vanderVeld
Velden).
1083-8791/$ e see front matter 
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
A role for gut bacteria in the pathogenesis of graft-versus-host disease (GVHD) has been ﬁrmly established;
however, the role of Candida spp, which form part of the mycobiome, remains unknown. In a homogenous group
of patients who underwent allogeneic stem cell transplantation (SCT), we found a signiﬁcant impact of Candida
colonization on the occurrence of acute GVHD. Patients colonized with Candida spp developed signiﬁcantly more
grade II-IV acute GVHD compared with noncolonized patients (50% vs 32%; P ¼ .03), as well as more gastroin-
testinal (GI)-GVHD (33% vs 19%; P ¼ .05). Colonization with Candida spp was more frequent in patients bearing
the loss-of-function polymorphism Y238X, which results in dectin-1 dysfunction, compared with patients with
the wild-type allele (73% vs 31%; P ¼ .002). There was no direct effect of dectin-1 dysfunction on acute GVHD,
although it did inﬂuence the occurrence of GVHD indirectly through Candida colonization. The exact mechanism
of GVHD induction by Candida spp colonization of the mucosa is unknown, but the link might prove to be the
induction of Th 17/IL-23 responses through activation of pattern recognition receptors by fungal motifs, including
b-D-glucan andmannans. These data indicate a role for the mycobiome in the pathogenesis of GVHD and suggest
that altering the mycobiome by antifungal drugs can help ameliorate GI-GVHD. In addition, given that the genetic
constitution of patients affects susceptibility to both Candida colonization and GVHD, whether identifying
gene polymorphisms will facilitate personalized treatment of SCT recipients remains to be determined.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Recently, interest has been revived in the role of mucosal
innate immunity and the gastrointestinal (GI) microbiota in
the pathogenesis of both chemotherapy-induced intestinal
mucositis and graft-versus-host disease (GVHD) after allo-
geneic stem cell transplantation (SCT) [1,2]. The interac-
tions among the innate immune system, gut commensal
bacteria, and donor T cells are complex and often multidi-
rectional. On the one hand, perturbed mucosal innate
immunity resulting from cytotoxic therapy or gene poly-
morphisms, along with changes in the composition and
number of gastrointestinal microbiota (dysbiosis), can
aggravate inﬂammation of the intestinal mucosal barriers
and stimulate alloreactive T cell responses, inducing GVHD
[3,4]. On the other hand, damage to the GI tract induced
by GVHD alters the host response by, for instance,
T cellemediated Paneth cell damage, resulting in decreased
release of a-defensin, with subsequent dysbiosis and
increased risk for bacteremia, fungemia, and perpetuation
of GVHD [5].
A role for gut bacteria in the pathogenesis of GVHD was
postulated almost 40 years ago [6], and selective gutdgments on page 332.
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12.11.008decontamination has been associated with a decreased
incidence of acute GVHD [7]. However, the role of intestinal
Candida spp, which forms part of the mycobiome, has not
yet been studied in GVHD. Given the similarities between
inﬂammatory bowel disease (IBD) and GI-GVHD, under-
standing the role of Candida spp in IBD might provide
insight into a possible role in GI-GVHD as well [8]. Iliev et al.
[9] recently reported an important role of the mycobiome
and changes therein, in the severity of experimental colitis
in animals. Defective innate immune responses caused by
dectin-1 deﬁciency resulted in increased colonization with
Candida spp, which aggravated chemically induced colitis;
these effects were counteracted by treatment with ﬂuco-
nazole. Dectin-1 is a pivotal pattern recognition receptor
that recognizes the b-D-glucan found in fungal cell walls,
including those of Candida and triggers mucosal antifungal
CD4þ Th17 responses [10]. The release of IL-17 and IL-22
is a key aspect of mucosal antifungal defenses, stimu-
lating the release of antimicrobial peptides, including Reg
proteins and defensins and recruitment of neutrophils.
Interestingly, a- and b-defensins also have strong antimi-
crobial activity against Candida species. Dysfunctional
dectin-1 has clinical implications for humans, with the loss-
of-function single-nucleotide polymorphism (SNP; Y238X,
rs16910526) linked to increased susceptibility to mucosal
fungal infections [10].
Given the relationship between Candida colonization and
IBD, we wondered whether the intestinal mycobiome also
might play a role in the pathogenesis of GVHD, particularly in
GI-GVHD. Thus, we investigated whether Candida coloniza-
tion and dectin-1 function had any effect on the develop-
ment of GVHD.
Table 1
Patient, Donor, and Transplantation Characteristics
Characteristic Value
Patient age, yr, median (range) 48 (18-64)
Patient sex, male/female, n 97/56
Donor age, yr, median (range) 46 (20-65)
Donor sex, male/female, n 92/61
Donorerecipient sex match, n (%)
Female donoremale recipient 41 (27)
Other 112 (73)
Diagnosis, n (%)
AML/MDS/ALL 102 (67)
Other 51 (33)
Myeloablative conditioning, n (%)
Idarubicin-cyclophosphamide-TBI 103 (67)
Idarubicin-cyclophosphamide-busulfan 13 (9)
Cyclophosphamide-TBI 29 (19)
Cyclophosphamide-busulfan 8 (5)
T cell depletion technique, n (%)
Elutriation 33 (21.5)
CD34 selection 65 (42.5)
CD3/CD19 depletion 55 (36)
Stem cell source, n (%)
Bone marrow 48 (31)
Peripheral blood 105 (69)
Graft CD34þ cells,  106/kg, median, range 3.0 (0.8-11.0)
Graft CD3þ cells,  106/kg, median, range 0.5 (0.3-0.7)
GVHD prophylaxis with cyclosporine A, n (%) 153 (100)
Acute GVHD, n (%)
Grade II-IV 59 (38.5)
Grade III-IV 25 (16)
Acute GI-GVHD grade I-IV, n (%) 37 (24)
Candida colonization, n (%) 54 (35)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; MDS, myelodysplastic syndrome; TBI, total body irradiation.
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Study Population and Treatment Protocol
We performed a retrospective analysis in a highly homogenous group of
153 patients who had undergone matched-related partially T celledepleted
allogeneic SCT after myeloablative conditioning (Table 1). All patients had
received only cyclosporine for GVHD prophylaxis, along with selective
antimicrobial prophylaxis consisting of ciproﬂoxacin during the ﬁrst weeks
after SCT [11].
Candida colonization was evaluated within the ﬁrst 7 to 10 days after
admission and was deﬁned as the presence of Candida spp in a fecal sample
and mouthwash sample obtained on the same day, or recovery of Candida
spp from samples obtained from the same site on 2 consecutive occasions.
Fluconazole 200 mg/day was prescribed only for those patients colonized
with Candida albicans, Candida tropicalis, or Candida parapsilosis and not for
patients colonized with species likely to be resistant to the drug, such as
Candida krusei and Candida glabrata. Acute GVHD and GI-GVHDwere scored
according to the criteria of Przepiorka et al. [12].Detection of Dectin-1 SNP Y238X
DNA for genotyping was available for a subset of 127 patients and their
donors. Genotyping for the presence of the Y238X polymorphism in the
patient group was performed as described previously [11]. All patients
provided informed consent for the prospective collection of DNA samples
for investigational use.Statistical Analysis
We ﬁrst performed a univariate analysis of the impact of Candida
colonization and other factors on the development of acute GVHD grade II-
IV and GI-GVHD grade I-IV. Factors with P < .20 in the univariate analysis
were then incorporated into a backward logistic regression analysis; the
criterion for remaining in the model was a likelihood ratio associated with
P < .05. The chi-square test was used to compare the rate of Candida colo-
nization in patients with and without the dectin-1 polymorphism. SPSS
software (IBM, Armonk, NY) was used for statistical analyses and generation
of probability curves for GVHD. A P value < .05 was considered statistically
signiﬁcant.RESULTS
Candida Colonization Increases GVHD
The overall incidence of acute GVHD and GI-GVHD after
partially T celledepleted SCT with myeloablative conditioning
was 38.5% (59 of 153) and 24% (37 of 153), respectively.
Approximately 35% of the patients (54 of 153) were colonized,
mainly with C albicans (85%), with C glabrata, C krusei, C par-
apsilosis, and C tropicalis accounting for the remainder.
Patients colonized with Candida spp had a signiﬁcantly higher
rate of grade II-IV acute GVHD compared with uncolonized
patients (50% [27 of 54] vs 32% [32 of 99]; OR, 2.0; 95%
conﬁdence interval [CI], 1.05-4.13; P ¼ .038) (Table 2 and
Figure 1A). After multivariate analysis, Candida colonization
was the only signiﬁcant factor remaining (P¼ .034), with stem
cell source and method of T cell depletion no longer signiﬁ-
cant. Patient colonized with Candida spp were also more
prone to developing GI-GVHD, but the difference failed to
reach nominal statistical signiﬁcance (33% [18 of 54] vs 19%
[19/99]; OR, 2.11; 95% CI, 0.99-4.48; P ¼ .07) (Table 2 and
Figure 1B). Backward logistic regression analysis, however,
showed signiﬁcant relationships between GI-GVHD and
Candida colonization (P¼ .049) and stem cell source (P¼ .016)
(Table 2). In our cohort, 45 patients experienced isolated grade
I-IV skin GVHD. Colonization with Candida spp had no
signiﬁcant impact on the incidence of isolated skin GVHD (48%
[15 of 31] of patients colonized with Candida vs 42% [30 of 71]
of noncolonized patients; P ¼ .66).
Fluconazole 200 mg/day was prescribed in 83% (45 of 54)
of the patients colonized with Candida spp. The patients not
receiving ﬂuconazole were colonized mainly with C glabrata
and C krusei. Fluconazole therapy was initiated late, in the
second or third week after admission, in patients with
established neutropenia and mucosal barrier damage. Thus,
although the fungal burden was decreased in some patients,
eradication of Candida spp was achieved in only 35% (16 of
45) of colonized patients. Colonized patients who received
ﬂuconazole had a slightly lower risk of developing GVHD
compared with colonized patients who did not receive ﬂu-
conazole (47% [21 of 45] vs 67% [6 of 9]); however, the
number of patients was too small to allow detection of
a signiﬁcant difference (P ¼ .47).
Dectin-1 Polymorphism Y238X, Candida Colonization,
and GVHD
Fifteen patients (12%) were heterozygous for the dectin-1
SNP, and 112 (88%) were homozygous for the wild-type
allele. The genotype frequencies in the study cohort
showed Hardy-Weinberg equilibrium with an allele
frequency of 6%, as has been reported previously. Coloniza-
tion with Candida spp was more frequent in patients bearing
the dectin-1 SNP compared with those with the wild-type
allele (73% [11 of 15] vs 31% [35 of 112]; P ¼ .002). Dectin-1
mutation status had no impact on the incidence of acute
GVHD, being 30% in both groups (Figure 2); nevertheless,
45% (5 of 11) of the patients with both the dectin-1 mutation
and Candida colonization had acute GVHD, a rate similar to
that in the total group of colonized patients. Conversely,
none of the 4 noncolonized patients with the mutation had
acute GVHD; however, the number of patients is too small to
permit a meaningful statistical analysis.
DISCUSSION
We found a signiﬁcant impact of Candida colonization on
the rates of acute GVHD, and of GI-GVHD, in a homogenous
group of patients who underwent allogeneic SCT. However, no
Table 2
Univariate and multivariate analysis of risk factors for acute GVHD and GI-GVHD
Variable No. Acute GVHD grade II-IV Acute GI-GVHD
OR (95% CI) P Value* P Valuey OR (95% CI) P Value* P Valuey
Conditioning
No total body irradiation 21 1 1
Total body irradiation 132 1.68 (0.61-4.60) .35 d 2.08 (0.58-7.51) .41 d
Diagnosis
Other diagnoses 51 1 1
AML/MDS/ALL 102 1.59 (0.78-3.24) .22 d 1.48 (0.65-3.35) .43 d
Donorerecipient sex match
Other 112 1 1
Female donoremale
recipient
41 0.89 (0.43-1.87) .89 d 1.21 (0.54-2.75) .67 d
T cell depletion
Elutriation 33 1 1
CD34 selection 65 1.35 (0.55-3.3) .65 3.00 (0.80-11.23) .11
CD3/CD19 depletion 55 1.92 (0.77-4.77) .18 NS 5.28 (1.42-19.57) .01 NS
Age group
<50 yr 88 1 1
50 yr 65 1.24 (0.64-2.40) .6 d 1.61 (0.76-3.38) .25 d
Stem cell source
Bone marrow 48 1 1
Peripheral blood 105 1.82 (0.86-3.79) .11 NS 2.93 (1.13-7.60) .025 .016
Candida colonization
No 99 1 1
Yes 54 2.09 (1.05-4.13) .038 .033 2.11 (0.99-4.48) .07 .049
Dectin-1 statusz
Wild-type 112 1 1
Polymorphism 15 1.06 (0.34-3.34) 1.00 d 1.22 (0.31-4.78) .72 d
NS indicates not signiﬁcant; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome.
* Univariate analysis (chi-square test).
y Backward logistic regression analysis; only factors with a P value < .20 on univariate analysis were incorporated.
z Dectin-1 status was determined in 127 patients.
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isolated acute skin GVHD. There was also a strong association
between dectin-1 dysfunction, caused by the loss-of-function
SNP Y238X and mucosal Candida colonization in this setting,
as reported previously [11]. Although the subgroup of patients
carrying the dectin-1 mutation was small, there seems to be
no direct effect of dectin-1 dysfunction on acute GVHD, sug-
gesting that dectin-1 dysfunction inﬂuences GVHD only
indirectly through Candida colonization. Our human data are
in line with ﬁndings in an IBD mouse model reported by Iliev
et al. [9]. Moreover, our ﬁndings are supported by the results
of Marr et al. in 2000 [13]. Although designed to assess
the impact of ﬂuconazole prophylaxis (400 mg/day starting at
the initiation of conditioning therapy and extending for up
to 120 days) on Candida infection and candidiasis-related
mortality in allogeneic SCT, that study also found aFigure 1. Incidence of acute GVHD in relation to Candida colonization. Shown are tim
colonized with Candida spp (green line) and patients not colonized (blue line).decreased incidence of GI-GVHD in the patients receiving
ﬂuconazole compared with those who did not receive ﬂuco-
nozole (5.5% vs 14%; P ¼ .02). In our cohort, the use of ﬂuco-
nazole was not associated with a signiﬁcant reduction in
GVHD; however, but this lack of effect was likely related to the
delayed start and lower dose of ﬂuconazole therapy, resulting
in a late and modest effect on fungal burden in colonized
patients, demonstrated by an eradication rate of only 35%.
The exact mechanism of GVHD induction by Candida spp
colonization of the mucosa is currently unknown, but there
likely are similarities with the mechanisms through which
gut bacteria aggravate GVHD [1]. Translocation of Candida
motifs, such as b-D-glucan andmannans, during conditioning
therapyeinduced mucosal damage can aggravate both local
mucosal and systemic immune responses through activation
of different pattern recognition receptors (PRRs), moste-dependent occurrence of GVHD grade II-IV (A) and GI-GVHD (B) in patients
Figure 2. Candida colonization, dectin-1 status, and GVHD. Dectin-1 single-
nucleotide polymorphism Y238X resulted in signiﬁcantly more Candida
colonization but had no direct effect on acute GVHD grade II-IV.
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like receptor 2 [14]. These PRRs are expressed on several
types of immune cells, including dendritic cells and other
antigen-presenting cells and cause the release of proin-
ﬂammatory cytokines and induce Th1 and Th17 responses on
activation. Th17 responses are known to be most important
in anti-Candida host defenses at the mucosal barrier [15,16],
and interestingly, recent studies have also revealed a role for
Th17/IL-23 in the pathogenesis of acute GVHD in both
animals and humans, including GI-GVHD [17-19]. Thus, the
link between Candida colonization and acute GVHD might
prove to be in the induction of Th17/IL-23 responses, espe-
cially when the fungus is present in the gut. However, dectin-
1 dysfunction owing to the Y238X polymorphism results in
decreased mucosal Th17 responses [20], which on the one
hand explains the increased Candida colonization, but on the
other hand also suggests that dectin-1 dysfunction might
ameliorate GVHD. This seems to not be the case, however, as
demonstrated by our data. The most likely explanation is the
existence of some degree of redundancy in PRR activation by
Candida spp. Thus, despite the dectin-1 dysfunction, the
activation of other PRRs by the presence of an increased
fungal burden increases mucosal immune responses that
aggravate GVHD. Clearly, additional experimental studies are
needed to shed light on these hypotheses.
In conclusion, colonization with Candida has a signiﬁcant
inﬂuence on the occurrence of acute GVHD, including
GI-GVHD, in humans, indicating a role of the mycobiome in
the pathogenesis of GVHD. The dectin-1 SNP Y238X muta-
tion increases the likelihood of Candida colonization but
appears to have only an indirect role in causing GVHD. A role
of gut bacteria has long been implicated in the pathogenesis
of acute GVHD, and although the focus to now has been on
gut bacteria, our data reported here underscore the impor-
tance of the gutmycobiome. The use of ﬂuconazole and other
antifungal drugs in SCT recipients is being increasingly
advocated to prevent fungal infections, but our ﬁndings
suggest that it might ameliorate GI-GVHD as well. However,
timely initiation of antifungal drugs (ie, at the start of the
conditioning) at the proper dosage might prove essential for
effective reduction of the fungal burden and thus protection
against GVHD. It would be of interest to test whether altering
the mycobiome composition by means other than antifungal
drugs, such as with the use of prebiotics or probiotics, can be
exploited to reduce the incidence of GVHD. Given that anindividual’s genetic constitution affects susceptibility to both
Candida colonization and GVHD, it remains to be seen
whether identifying the gene polymorphisms will help
achieve personalized treatment of SCT recipients, exposing
only those who will beneﬁt from antifungal agents, thereby
reducing the use of drugs and any concomitant side effects,
decreasing the risk of selecting antifungal resistance, and
helping control associated costs.
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